Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-I in Human Breast Cancer

TİMUR S. S. , Bhattarai P., GÜRSOY R. N. , VURAL İ. , Khaw B.

PHARMACEUTICAL RESEARCH, vol.34, no.2, pp.352-364, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.1007/s11095-016-2066-2
  • Page Numbers: pp.352-364


Purpose LyP-1, a nine-amino-acid tumor homing peptide, selectively binds to its cognate receptor, p32. Overexpression of p32 in certain tumors should allow use of LyP-1 as a targeting agent for the delivery of therapeutic or diagnostic agents. Peptide conjugates are developed for enhanced pretargeting of MDA-MB-231 breast cancer cells with peptideantibody bispecific complexes and targeting with multipledrug/- fluorophore-conjugated nano-polymers.